Otitis Media Clinical Trial
Official title:
Nasal Xylitol for Recurrent Otitis Media
Verified date | October 2023 |
Source | Rambam Health Care Campus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Acute otitis media (AOM) is one of the most prevalent and costly illnesses in children throughout the world. AOM can lead to chronic otitis media with effusion (OME) resulting in conductive hearing loss that can cause speech, language, academic, and social developmental delays. Complementary and alternative medicines are being widely used for prevention of AOM. Xylitol is a five carbon polyol (sugar alcohol) produced from natural plants and is used for preventing dental caries and AOM in children. It is commercially available in chewing gums, syrups and toothpastes washes, and other products. Xylitol was shown in several studies to prevent the culture of bacteria in the nasopharynx and oral cavity. It was proven to eliminate the ability of bacteria to attach to the mucosa of the upper respiratory system. It was proven to reduce the ability of bacteria to attach to the mucosa of the upper respiratory system. Previous study had shown that oral usage of Xylitol (as chewing gum or syrup) can reduce the incidence of rAOM by 30% as compared to placebo. But this treatment did not gain popularity since the initial clinical trial 30 years. There are several potential reasons for that. First, Xylitol should be administrated 5 times daily in order to be effective. Study that checked usage of oral Xylitol 3 times daily in children with rAOM did not find additional advantage as compared to placebo. Secondly, by using Xylitol orally we rely on the gut absorption and systemic distribution. Xylitol absorbs poorly in the gut and can cause some GI symptoms (like nausea and diarrhea) especially when used in a syrup (the preferred way in small children). In this study the investigators aim to test the yield of Xylitol nasal spray as a preventive treatment in children with rAOM. By using Xylitol as nasal spray we deliver the active compound directly to the action site (nasopharynx- the AOM reservoir) and avoid the GI side effects
Status | Completed |
Enrollment | 70 |
Est. completion date | September 1, 2023 |
Est. primary completion date | August 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 5 Years |
Eligibility | Inclusion Criteria: 1. Children at the age of 1-5 years that suffered from recurrent otitis media (3 episodes in the last 6 months prior to entrance to the study) Exclusion Criteria: 1. Children with immune deficiency 2. Children with craniofacial malformations 3. Children with chronic otitis media 4. Children that received prophylactic antibiotic treatment prior to entering the study (3 months ) |
Country | Name | City | State |
---|---|---|---|
Israel | Carmel Medical Center | Haifa | |
Israel | Rambam Health Care Campus | Haifa |
Lead Sponsor | Collaborator |
---|---|
Rambam Health Care Campus | Carmel Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Antimicrobial treatment | Collect the type (systemic or topical) of antimicrobial treatment prior and during the study | 9 months | |
Other | Parental diary | The parents will conduct a diary that will include AOM episodes, who made the diagnosis, what were the symptoms and what kind of treatment was given. | 6 months | |
Primary | prevalence of otitis media episodes | The number of events of acute otitis media during the study period of 6 months. The comparison is in 3 months intervals. pre-treatment, during treatment and post-treatment | 6 months | |
Secondary | Side effects of treatment | any side effects of the treatment will be recorded | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04016051 -
Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT02452164 -
Family MobilePhone Otoscopy in Diagnostics of Otitis Media
|
N/A | |
Completed |
NCT01199016 -
Effect of Prevnar 13 on Ear Infections in Children
|
Phase 4 | |
Terminated |
NCT00778063 -
Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients
|
N/A | |
Completed |
NCT00195611 -
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
|
Phase 4 | |
Recruiting |
NCT03722160 -
Clinical Study of the Solo Tympanostomy Tube Device
|
N/A | |
Recruiting |
NCT04447521 -
Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium
|
||
Active, not recruiting |
NCT05127161 -
Broad Implementation of Outpatient Stewardship
|
N/A | |
Completed |
NCT02600559 -
Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes
|
Phase 3 | |
Completed |
NCT01444391 -
inVENT-visIOn Study
|
N/A | |
Enrolling by invitation |
NCT01437436 -
The Effect of Obesity on Ventilation Tube Insertion
|
N/A | |
Completed |
NCT01003210 -
Homeopathic Ear Drops for Otitis Media Study
|
N/A | |
Completed |
NCT00768534 -
Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media
|
N/A | |
Recruiting |
NCT00393159 -
The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children
|
Phase 4 | |
Completed |
NCT00617682 -
Maternal Immunization To Prevent Infant Otitis Media
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00956748 -
N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media
|
Phase 4 | |
Withdrawn |
NCT01908764 -
Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery
|
Phase 1 | |
Recruiting |
NCT01619462 -
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
|
Phase 3 | |
Completed |
NCT02616458 -
The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population
|
N/A | |
Completed |
NCT00044473 -
A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat
|
Phase 3 |